NewLink Genetics launches Phase 1 clinical trial of HyperAcute Immunotherapy NewLink Genetics announced that it had launched a first in human Phase 1 clinical trial of HyperAcute Renal immunotherapy in patients with metastatic renal cell cancer. HyperAcute Renal Immunotherapy is comprised of two allogeneic renal cell cancer cell lines engineered to express the murine alpha GT gene. The Phase 1 dose-escalation study is designed primarily to determine the safety of HyperAcute Renal immunotherapy cells administered by intradermal injection in up to 20 patients with recurrent or refractory, metastatic clear-cell renal cancer.
News For NLNK From The Last 14 Days
Check below for free stories on NLNK the last two weeks.
NewLink pancreatic cancer vaccine a 'long shot,' says Summer Street After hosting a conference call, Summer Street calls NewLink Genetics' vaccine for pancreatic cancer a "long shot." The firm says it doubts the phase III testing will be successful.